ArticleBMC medicine2024
Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes.
Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Relationship between participant-reported outcomes, residual beta cell function and metabolic parameters in youth with newly diagnosed type 1 diabetes.Diabetologia · 2026Trial
- Artificial Pancreas and Closed-Loop Insulin Delivery: From Early Concepts to AI-Driven Diabetes Automation.Biosensors · 2026Review
- HbA1c improvement in pregnant women with type 1 diabetes using the CamAPS FX automated insulin delivery (AID) system: Clinical and economic outcomes.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- Implementation of Video Consultations Within a Personalized Hybrid Care Model for Children and Adolescents with Type 1 Diabetes Using Automated Insulin Delivery Systems: A Real-World Descriptive Study.Journal of personalized medicine · 2026Article
- Outcomes of Diabetes Management with Continuous Glucose Monitoring Technology.Archives of internal medicine research · 2026Article
- Cost-Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries.Diabetes, obesity & metabolism · 2026Article
- Article
- Nanostructured electrode materials and flexible-substrate engineering for wearable multi-analyte biosensors in diabetes monitoring and personalized care: a comprehensive review.Journal of materials science. Materials in medicine · 2026Review
- Long-term effectiveness of automated insulin delivery in young people with type 1 diabetes: a meta-analysis.Diabetology & metabolic syndrome · 2026Article
- Glycemic Outcomes and Device Engagement Over 18 Months Following Initiation of Two Different Automated Insulin Delivery Systems in American Youth With Type 1 Diabetes.Diabetes technology & therapeutics · 2026Article
- [Effect of glycemic variability on the efficacy of artificial pancreas systems: A real-world study].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Fully closed-loop systems: can people with type 1 diabetes just do it? Insights from open-source systems.Diabetologia · 2026Review
- Patient, family and provider experiences with a very low-carbohydrate approach for type 1 diabetes.Journal of metabolic health · 2026Article
- Effect of Atmospheric Temperature Variations on Glycemic Patterns of Patients with Type 1 Diabetes: Analysis as a Function of Different Therapeutic Treatments.International journal of environmental research and public health · 2025Article
- Hybrid closed-loop systems in UK type 1 diabetes care: National survey of healthcare professional awareness, confidence, and training needs.Diabetes, obesity & metabolism · 2025Article
- Dynamics and determinants of long-term quality of life in children and adolescents with type 1 diabetes: real-world evidence from China.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Hybrid Closed-Loop Therapy in Adults with Type 1 Diabetes in England: Long-Term Outcomes from a Real-World Observational Study.Diabetes technology & therapeutics · 2025Observational
- Low parental stress and positive well-being in Finnish children and adolescents with type 1 diabetes.BMJ open diabetes research & care · 2025Article
- Ethnicity and socioeconomic status do not influence glycaemic outcomes of a tubeless hybrid closed-loop system (Omnipod® 5) in adults with type 1 diabetes.Diabetes, obesity & metabolism · 2025Observational
- Sociodemographic inequities and use of hybrid closed-loop systems associated with obesity in youth with type 1 diabetes.Diabetes research and clinical practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hybrid closed-loop (HCL) systems seamlessly interface continuous glucose monitoring (CGM) with insulin pumps, employing specialised algorithms and user-initiated automated insulin delivery. This study aimed to assess the efficacy of HCLs at 12 months post-initiation on glycated haemoglobin (HbA1c), time-in-range (TIR), hypoglycaemia frequency, and quality of life measures among children and young people (CYP) with type 1 diabetes mellitus (T1DM) and their caregivers in a real-world setting. Conducted between August 1, 2021, and December 10, 2022, the prospective recruitment took place in eight paediatric diabetes centres across England under the National Health Service England's (NHSE) HCL pilot real-world study. A cohort of 251 CYP (58% males, mean age 12.3 years) with T1DM participated (89% white, 3% Asian, 4% black, 3% mixed ethnicity, and 1% other). The study utilised three HCL systems: (1) Tandem Control-IQ AP system, which uses the Tandem t:slim X2 insulin pump (Tandem Diabetes Care, San Diego, CA, USA) with the Dexcom G6® CGM (Dexcom, San Diego, CA, USA) sensor; (2) Medtronic MiniMed™ 780G with the Guardian 4 sensor (Medtronic, Northridge, CA, USA); and (3) the CamAPS FX (CamDiab, Cambridge, UK) with the Ypsomed insulin pump (Ypsomed Ltd, Escrick, UK) and Dexcom G6® CGM.All systems were fully funded by the NHS. Results demonstrated significant improvements in HbA1c (average reduction at 12 months 7 mmol/mol; P < 0.001), time-in-range (TIR) (average increase 13.4%; P < 0.001), hypoglycaemia frequency (50% reduction), hypoglycaemia fear, and quality of sleep (P < 0.001) among CYP over a 12-month period of HCL usage. Additionally, parents and carers experienced improvements in hypoglycaemia fear and quality of sleep after 6 and 12 months of use. In addition to the improvements in glycaemic management, these findings underscore the positive impact of HCL systems on both the well-being of CYP with T1DM and the individuals caring for them.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.